Literature DB >> 16934468

Severe phenotype in infantile facioscapulohumeral muscular dystrophy.

Lars Klinge1, Michelle Eagle, Irene D Haggerty, Catherine E Roberts, Volker Straub, Kate M Bushby.   

Abstract

While much is known about the clinical course of adult FSHD, the third most common inherited muscular dystrophy, data on the "infantile phenotype" and especially on the progression of the disease in children are limited. We have followed a cohort of 7 patients with infantile FSHD for 9-25 years and here report the clinical and genetic findings in this group. Infantile FSHD is relatively rare, amounting to 4% of all of our FSHD patients. Despite some variability in the progression, infantile FSHD has a more consistent phenotype than adult FSHD. Although they had normal motor milestones, all patients showed facial weakness from early childhood, and subsequently were severely affected with rapid progression of the disease, marked muscular wasting, weakness, and hyperlordosis. None of the patients have shown signs of nocturnal hypoventilation or cardiomyopathy so far. No correlation was found between sex and the severity of phenotype whereas all but one patient had very short fragment sizes of the D4Z4 repeat. Only two patients had a de novo mutation: 3 patients inherited the mutation from a parent with somatic mosaicism, and one was inherited from a parent with classical adult FSHD. One patient was unusual in having one allele inherited from his father who showed somatic mosaicism and one allele with an additional de novo mutation. We conclude that infantile FSHD is a severe and rapidly progressive disease, and this needs to be taken into account in the advice given to patients diagnosed in early childhood. However, our data also suggest that the risk to an individual with classical FSHD of having a child with the infantile form is low.

Entities:  

Mesh:

Year:  2006        PMID: 16934468     DOI: 10.1016/j.nmd.2006.06.008

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  24 in total

1.  Genetic counseling and testing for FSHD (facioscapulohumeral muscular dystrophy) in the Israeli population.

Authors:  Miri Yanoov-Sharav; Esther Leshinsky-Silver; Sarit Cohen; Chana Vinkler; Marina Michelson; Tally Lerman-Sagie; Mira Ginzberg; Menahem Sadeh; Dorit Lev
Journal:  J Genet Couns       Date:  2011-11-23       Impact factor: 2.537

2.  Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity.

Authors:  Emanuela Teveroni; Marsha Pellegrino; Sabrina Sacconi; Patrizia Calandra; Isabella Cascino; Stefano Farioli-Vecchioli; Angela Puma; Matteo Garibaldi; Roberta Morosetti; Giorgio Tasca; Enzo Ricci; Carlo Pietro Trevisan; Giuliana Galluzzi; Alfredo Pontecorvi; Marco Crescenzi; Giancarlo Deidda; Fabiola Moretti
Journal:  J Clin Invest       Date:  2017-03-06       Impact factor: 14.808

3.  Orthognathic surgery in a case of infantile facioscapulohumeral muscular dystrophy with macroglossia.

Authors:  Marcus Stephan Kriwalsky; Marcus Deschauer; Alexander Walter Eckert; Johannes Schubert; Stephan Zierz
Journal:  Oral Maxillofac Surg       Date:  2008-12

4.  Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy.

Authors:  Kenji Rowel Q Lim; Rika Maruyama; Yusuke Echigoya; Quynh Nguyen; Aiping Zhang; Hunain Khawaja; Sreetama Sen Chandra; Takako Jones; Peter Jones; Yi-Wen Chen; Toshifumi Yokota
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-29       Impact factor: 11.205

5.  New multiplex PCR-based protocol allowing indirect diagnosis of FSHD on single cells: can PGD be offered despite high risk of recombination?

Authors:  Mouna Barat-Houari; Karine Nguyen; Rafaëlle Bernard; Céline Fernandez; Catherine Vovan; Corinne Bareil; Philippe Khau Van Kien; Delphine Thorel; Sylvie Tuffery-Giraud; Francis Vasseur; Shahram Attarian; Jean Pouget; Anne Girardet; Nicolas Lévy; Mireille Claustres
Journal:  Eur J Hum Genet       Date:  2009-11-25       Impact factor: 4.246

6.  Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy.

Authors:  Rianne J M Goselink; Karlien Mul; Caroline R van Kernebeek; Richard J L F Lemmers; Silvère M van der Maarel; Tim H A Schreuder; Corrie E Erasmus; George W Padberg; Jeffrey M Statland; Nicol C Voermans; Baziel G M van Engelen
Journal:  Neurology       Date:  2018-12-19       Impact factor: 9.910

Review 7.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

8.  DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.

Authors:  Lindsay M Wallace; Sara E Garwick; Wenyan Mei; Alexandra Belayew; Frederique Coppee; Katherine J Ladner; Denis Guttridge; Jing Yang; Scott Q Harper
Journal:  Ann Neurol       Date:  2010-12-08       Impact factor: 10.422

9.  A multinational study on motor function in early-onset FSHD.

Authors:  Jean K Mah; Jia Feng; Marni B Jacobs; Tina Duong; Kate Carroll; Katy de Valle; Cara L Carty; Lauren P Morgenroth; Michela Guglieri; Monique M Ryan; Paula R Clemens; Mathula Thangarajh; Richard Webster; Edward Smith; Anne M Connolly; Craig M McDonald; Peter Karachunski; Mar Tulinius; Amy Harper; Avital Cnaan; Yi-Wen Chen
Journal:  Neurology       Date:  2018-03-14       Impact factor: 9.910

Review 10.  The cell biology of disease: FSHD: copy number variations on the theme of muscular dystrophy.

Authors:  Daphne Selvaggia Cabianca; Davide Gabellini
Journal:  J Cell Biol       Date:  2010-12-13       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.